BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

Freeline has posted clinical potency data for its hemophilia B gene therapy that suggest its treatment could outperform its more advanced competitors. Chris Hollowood, Freeline Therapeutics Ltd. executive chairman and Syncona Ltd. chief investment officer,...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Feb 5, 2020
Politics, Policy & Law

Trump boosts Grassley-Wyden drug pricing bill

President Donald Trump and Vice President Mike Pence have publicly endorsed pending Senate legislation that seeks to restructure the Medicare Part D drug benefit and impose inflation caps on prescription drug prices. “I’ve been speaking...
Items per page:
1 - 10 of 9702
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

Rising serial entrepreneur Akiko Iwasaki aims to bring antitumor immunity to the brain by opening the brain’s lymphatics, a recently discovered system of vessels just starting to find translational uses. In 2015, a Nature paper...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

Freeline has posted clinical potency data for its hemophilia B gene therapy that suggest its treatment could outperform its more advanced competitors. Chris Hollowood, Freeline Therapeutics Ltd. executive chairman and Syncona Ltd. chief investment officer,...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

Former FDA Commissioner Scott Gottlieb joined the board of next-generation sequencing company Illumina Inc. (NASDAQ:ILMN). The new role is at least his fourth board appointment since stepping down from the agency last year. Along with...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Feb 5, 2020
Politics, Policy & Law

Trump boosts Grassley-Wyden drug pricing bill

President Donald Trump and Vice President Mike Pence have publicly endorsed pending Senate legislation that seeks to restructure the Medicare Part D drug benefit and impose inflation caps on prescription drug prices. “I’ve been speaking...
Items per page:
1 - 10 of 9702